(Q40655620)

22 September 2017

title

Recombinant tumour necrosis factor in the local therapy of malignant pleural effusion (English)

1 reference

22 September 2017

0 references

Rauthe G

1

1 reference

22 September 2017

Sistermanns J

series ordinal

2

1 reference

22 September 2017

publication date

1 February 1997

1 reference

European Journal of Cancer

22 September 2017

published in

1 reference

22 September 2017

volume

33

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

226-231

1 reference

Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. A comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

Chemical pleurodesis for malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900404-2

7 January 2021

10.1016/S0959-8049(96)00404-2

Identifiers

DOI

1 reference

22 September 2017

1 reference